<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38552385</PMID><DateCompleted><Year>2024</Year><Month>04</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1980-5322</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Clinics (Sao Paulo, Brazil)</Title><ISOAbbreviation>Clinics (Sao Paulo)</ISOAbbreviation></Journal><ArticleTitle>Reduced HDL-cholesterol in long COVID-19: A key metabolic risk factor tied to disease severity.</ArticleTitle><Pagination><StartPage>100344</StartPage><MedlinePgn>100344</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100344</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clinsp.2024.100344</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1807-5932(24)00021-8</ELocationID><Abstract><AbstractText>This controlled study investigated metabolic changes in non-vaccinated individuals with Long-COVID-19, along with their connection to the severity of the disease. The study involved 88 patients who experienced varying levels of initial disease severity (mild, moderate, and severe), and a control group of 29 healthy individuals. Metabolic risk markers from fasting blood samples were analyzed, and data regarding disease severity indicators were collected. Findings indicated significant metabolic shifts in severe Long-COVID-19 cases, mainly a marked drop in HDL-C levels and a doubled increase in ferritin levels and insulin resistance compared to the mild cases and controls. HDL-C and ferritin were identified as the leading factors predicted by disease severity. In conclusion, the decline in HDL-C levels and rise in ferritin levels seen in Long-COVID-19 individuals, largely influenced by the severity of the initial infection, could potentially play a role in the persistence and progression of Long-COVID-19. Hence, these markers could be considered as possible therapeutic targets, and help shape preventive strategies to reduce the long-term impacts of the disease.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 HCFMUSP. Published by Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Al-Zadjali</LastName><ForeName>Jamila</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sultan Qaboos University, Muscat, Oman.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Lawati</LastName><ForeName>Amal</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Oman Medical College, National University, Muscat, Oman.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Riyami</LastName><ForeName>Nafila</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Sultan Qaboos University Hospital, Muscat, Oman.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Farsi</LastName><ForeName>Koukab</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Sultan Qaboos University Hospital, Muscat, Oman.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Jarradi</LastName><ForeName>Najwa</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Sultan Qaboos University Hospital, Muscat, Oman.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boudaka</LastName><ForeName>Ammar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sultan Qaboos University, Muscat, Oman.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Barhoumi</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sultan Qaboos University, Muscat, Oman.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Lawati</LastName><ForeName>Mohsen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sultan Qaboos University, Muscat, Oman.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Khaifi</LastName><ForeName>Amani</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sultan Qaboos University, Muscat, Oman.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Musleh</LastName><ForeName>Asma</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sultan Qaboos University, Muscat, Oman.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gebrayel</LastName><ForeName>Prisca</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>International Society of Microbiota, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vaulont</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Paris, Institut Cochin, INSERM, CNRS, F-75014, Paris, France; Laboratory of Excellence GR-Ex, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peyssonnaux</LastName><ForeName>Carole</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Paris, Institut Cochin, INSERM, CNRS, F-75014, Paris, France; Laboratory of Excellence GR-Ex, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edeas</LastName><ForeName>Marvin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Paris, Institut Cochin, INSERM, CNRS, F-75014, Paris, France; Laboratory of Excellence GR-Ex, Paris, France. Electronic address: marvin.edeas@inserm.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saleh</LastName><ForeName>Jumana</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sultan Qaboos University Hospital, Muscat, Oman.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clinics (Sao Paulo)</MedlineTA><NlmUniqueID>101244734</NlmUniqueID><ISSNLinking>1807-5932</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008076">Cholesterol, HDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-73-2</RegistryNumber><NameOfSubstance UI="D005293">Ferritins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008076" MajorTopicYN="N">Cholesterol, HDL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005293" MajorTopicYN="N">Ferritins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062072" MajorTopicYN="N">Patient Acuity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Disease severity</Keyword><Keyword MajorTopicYN="N">Ferritin</Keyword><Keyword MajorTopicYN="N">HDL-cholesterol</Keyword><Keyword MajorTopicYN="N">Iron</Keyword><Keyword MajorTopicYN="N">Long-COVID-19</Keyword><Keyword MajorTopicYN="N">Metabolic changes</Keyword></KeywordList><CoiStatement>Conflicts of interest The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>30</Day><Hour>11</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>29</Day><Hour>19</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38552385</ArticleId><ArticleId IdType="pmc">PMC10998035</ArticleId><ArticleId IdType="doi">10.1016/j.clinsp.2024.100344</ArticleId><ArticleId IdType="pii">S1807-5932(24)00021-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Clinical management of COVID-19: interim guidance, 27 May 2020. https://apps.who.int/iris/handle/10665/332196. Accessed July 1, 2022.</Citation></Reference><Reference><Citation>Home/Institution Isolation for COVID-19 (DGDSC Version 2.0 April 2020). https://www.moh.gov.om/documents/10194/3903020/Isolation+guideline+April+5.pdf/d58faba3-fe33-58e0-b070-841ebb1e4e37. Accessed March 21, 2023.</Citation></Reference><Reference><Citation>Almas T., Malik J., Alsubai A.K., Ehtesham M., Laique T., Ishaq U., et al. Effect of COVID-19 on lipid profile parameters and its correlation with acute phase reactants: a single-center retrospective analysis. Ann Med Surg. 2022;78</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9134795</ArticleId><ArticleId IdType="pubmed">35637852</ArticleId></ArticleIdList></Reference><Reference><Citation>Avula A., Nalleballe K., Narula N., Sapozhnikov S., Dandu V., Toom S., et al. COVID-19 presenting as stroke. Brain Behav Immun. 2020;87:115&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7187846</ArticleId><ArticleId IdType="pubmed">32360439</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandyopadhyay D., Akhtar T., Hajra A., Gupta M., Das A., Chakraborty S., et al. COVID-19 pandemic: cardiovascular complications and future implications. Am J Cardiovasc Drugs. 2020;20(4):311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7310596</ArticleId><ArticleId IdType="pubmed">32578167</ArticleId></ArticleIdList></Reference><Reference><Citation>Barter P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., Fogelman A.M. Antiinflammatory properties of HDL. Circ Res. 2004;95(8):764&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pubmed">15486323</ArticleId></ArticleIdList></Reference><Reference><Citation>Birjmohun R.S., Hutten B.A., Kastelein J.J.P., Stroes E.S.G. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2005;45(2):185&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">15653014</ArticleId></ArticleIdList></Reference><Reference><Citation>Brainard J., ed. News at a glance. Science (80-). 2024;383(6678):8&#x2013;10. 10.1126/SCIENCE.ADN8375.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/SCIENCE.ADN8375</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Chee Y.J., Ng S.J.H., Yeoh E. Diabetic ketoacidosis precipitated by COVID-19 in a patient with newly diagnosed diabetes mellitus. Diabetes Res Clin Pract. 2020;164</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7194589</ArticleId><ArticleId IdType="pubmed">32339533</ArticleId></ArticleIdList></Reference><Reference><Citation>Claise C., Saleh J., Rezek M., Vaulont S., Peyssonnaux C., Edeas M. Low transferrin levels predict heightened inflammation in patients with COVID-19: new insights. Int J Infect Dis. 2022;116:74&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8688186</ArticleId><ArticleId IdType="pubmed">34952211</ArticleId></ArticleIdList></Reference><Reference><Citation>Deuel J.W., Lauria E., Lovey T., Zweifel S., Meier M.I., Z&#xfc;st R., et al. Persistence, prevalence, and polymorphism of sequelae after COVID-19 in unvaccinated, young adults of the Swiss Armed Forces: a longitudinal, cohort study (LoCoMo) Lancet Infect Dis. 2022;22(12):1694&#x2013;1702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9411260</ArticleId><ArticleId IdType="pubmed">36030795</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhama K., Patel S.K., Pathak M., Yatoo M.I., Tiwari R., Malik Y.S., et al. An update on SARS-CoV-2/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies. Travel Med Infect Dis. 2020;37</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7260597</ArticleId><ArticleId IdType="pubmed">32479816</ArticleId></ArticleIdList></Reference><Reference><Citation>Diarte-A&#xf1;azco E.M.G., M&#xe9;ndez-Lara K.A., P&#xe9;rez A., Alonso N., Blanco-Vaca F., Julve J. Novel Insights into the Role of HDL-Associated Sphingosine-1-Phosphate in Cardiometabolic Diseases. Int J Mol Sci. 2019;20(24):6273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6940915</ArticleId><ArticleId IdType="pubmed">31842389</ArticleId></ArticleIdList></Reference><Reference><Citation>Eberhardt N., Noval M.G., Kaur R., Amadori L., Gildea M., Sajja S., et al. SARS-CoV-2 infection triggers pro-atherogenic inflammatory responses in human coronary vessels. Nat Cardiovasc Res. 2023;2(10):899&#x2013;916.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10702930</ArticleId><ArticleId IdType="pubmed">38076343</ArticleId></ArticleIdList></Reference><Reference><Citation>Edeas M., Saleh J., Peyssonnaux C. Iron: innocent bystander or vicious culprit in COVID-19 pathogenesis? Int J Infect Dis. 2020;97:303&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7264936</ArticleId><ArticleId IdType="pubmed">32497811</ArticleId></ArticleIdList></Reference><Reference><Citation>Endo Y., Fujita M., Ikewaki K. HDL Functions-Current Status and Future Perspectives. Biomolecules. 2023;13(1):105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9855960</ArticleId><ArticleId IdType="pubmed">36671490</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon S.M., Amar M.J., Jeiran K., Stagliano M., Staller E., Playford M.P., et al. Effect of niacin monotherapy on high density lipoprotein composition and function. Lipids Health Dis. 2020;19(1):190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7441610</ArticleId><ArticleId IdType="pubmed">32825822</ArticleId></ArticleIdList></Reference><Reference><Citation>Haley M.J., White C.S., Roberts D., O'Toole K., Cunningham C.J., Rivers-Auty J., et al. Stroke Induces Prolonged Changes in Lipid Metabolism, the Liver and Body Composition in Mice. Transl Stroke Res. 2020;11(4):837&#x2013;850.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7340675</ArticleId><ArticleId IdType="pubmed">31865538</ArticleId></ArticleIdList></Reference><Reference><Citation>Hojyo S., Uchida M., Tanaka K., Hasebe R., Tanaka Y., Murakami M., et al. How COVID-19 induces cytokine storm with high mortality. Inflamm Regen. 2020;40(1):37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7527296</ArticleId><ArticleId IdType="pubmed">33014208</ArticleId></ArticleIdList></Reference><Reference><Citation>Honda H., Takamatsu A., Miwa T., Tabuchi T., Taniguchi K., Shibuya K., et al. Prolonged symptoms after COVID-19 in Japan: a nationwide survey of the symptoms and their impact on patients&#x2019; quality of life. Am J Med. 2023 doi: 10.1016/j.amjmed.2023.04.040. Online ahead of print.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2023.04.040</ArticleId><ArticleId IdType="pmc">PMC10208656</ArticleId><ArticleId IdType="pubmed">37236416</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X., Chen D., Wu L., He G., Ye W. Declined serum high density lipoprotein cholesterol is associated with the severity of COVID-19 infection. Clin Chim Acta. 2020;510:105&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7350883</ArticleId><ArticleId IdType="pubmed">32653486</ArticleId></ArticleIdList></Reference><Reference><Citation>Janneh A.H., Kassir M.F., Dwyer C.J., Chakraborty P., Pierce J.S., Flume P.A., et al. Alterations of lipid metabolism provide serologic biomarkers for the detection of asymptomatic versus symptomatic COVID-19 patients. Sci Reports. 2021;11(1):1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8270895</ArticleId><ArticleId IdType="pubmed">34244584</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaji H. High-density lipoproteins and the immune system. J Lipids. 2013;2013:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3572698</ArticleId><ArticleId IdType="pubmed">23431458</ArticleId></ArticleIdList></Reference><Reference><Citation>Keene D., Price C., Shun-Shin M.J., Francis D.P. Effect on cardiovascular risk of high-density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients. BMJ. 2014;349:g4379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4103514</ArticleId><ArticleId IdType="pubmed">25038074</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasica R., Djukanovic L., Mrdovic I., Savic L., Ristic A., Zdravkovic M., et al. Acute Coronary Syndrome in the COVID-19 Era-Differences and Dilemmas Compared to the Pre-COVID-19 Era. J Clin Med. 2022;11(11):3024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9181081</ArticleId><ArticleId IdType="pubmed">35683411</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung T.Y.M., Chan A.Y.L., Chan E.W., Chan V.K.Y., Chui C.S.L., Cowling B.J., et al. Short- and potential long-term adverse health outcomes of COVID-19: a rapid review. Emerg Microbes Infect. 2020;9(1):2190&#x2013;2199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7586446</ArticleId><ArticleId IdType="pubmed">32940572</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G., Du L., Cao X., Wei X., Jiang Y., Lin Y., et al. Follow-up study on serum cholesterol profiles and potential sequelae in recovered COVID-19 patients. BMC Infect Dis. 2021;21(1):299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7989719</ArticleId><ArticleId IdType="pubmed">33761881</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Pan Y., Yin Y., Chen W., Li X. Association of dyslipidemia with the severity and mortality of Coronavirus Disease 2019 (COVID-19): a meta-analysis. Virol J. 2021;18(1):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8314261</ArticleId><ArticleId IdType="pubmed">34315474</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S., Wegman-Ostrosky T., Perelman C., Sepulveda R., Rebolledo P.A., Cuapio A., et al. More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis. medRxiv [Preprint] 2021 Jan 30 doi: 10.1101/2021.01.27.21250617. 2021.01.27.21250617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.27.21250617</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Maltezou H.C., Pavli A., Tsakris A. Post-COVID syndrome: an insight on its pathogenesis. Vaccines. 2021;9(5):497.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8151752</ArticleId><ArticleId IdType="pubmed">34066007</ArticleId></ArticleIdList></Reference><Reference><Citation>Mani P., Rohatgi A. Niacin therapy, HDL cholesterol, and cardiovascular disease: is the hdl hypothesis defunct? Curr Atheroscler Rep. 2015;17(8):43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4829575</ArticleId><ArticleId IdType="pubmed">26048725</ArticleId></ArticleIdList></Reference><Reference><Citation>Marfia G., Navone S., Guarnaccia L., Campanella R., Mondoni M., Locatelli M., et al. Decreased serum level of sphingosine-1-phosphate: a novel predictor of clinical severity in COVID-19. EMBO Mol Med. 2021;13(1):e13424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7744841</ArticleId><ArticleId IdType="pubmed">33190411</ArticleId></ArticleIdList></Reference><Reference><Citation>Masana L., Correig E., Ibarretxe D., Anoro E., Arroyo J.A., Jeric&#xf3; C., et al. Low HDL and high triglycerides predict COVID-19 severity. Sci Rep. 2021;11(1):7217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8010012</ArticleId><ArticleId IdType="pubmed">33785815</ArticleId></ArticleIdList></Reference><Reference><Citation>Mietus-Snyder M., Suslovic W., Delaney M., Playford M.P., Ballout R.A., Barber J.R., et al. Changes in HDL cholesterol, particles, and function associate with pediatric COVID-19 severity. Front Cardiovasc Med. 2022;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9597312</ArticleId><ArticleId IdType="pubmed">36312284</ArticleId></ArticleIdList></Reference><Reference><Citation>Mongio&#xec; L.M., Barbagallo F., Condorelli R.A., Cannarella R., Aversa A., La Vignera S., et al. Possible long-term endocrine-metabolic complications in COVID-19: lesson from the SARS model. Endocrine. 2020;68(3):467&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7266418</ArticleId><ArticleId IdType="pubmed">32488837</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni W., Yang X., Yang D., Bao J., Li R., Xiao Y., et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care. 2020;24(1):422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7356137</ArticleId><ArticleId IdType="pubmed">32660650</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu H.Q., Li Q., Rentfro A.R., Fisher-Hoch S.P., McCormick J.B. The definition of insulin resistance using HOMA-IR for Americans of Mexican descent using machine learning. PLoS ONE. 2011;6(6):e21041.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3114864</ArticleId><ArticleId IdType="pubmed">21695082</ArticleId></ArticleIdList></Reference><Reference><Citation>Samidurai A., Das A. Cardiovascular complications associated with COVID-19 and potential therapeutic&#x223c;strategies. Int J Mol Sci. 2020;21(18):1&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7554795</ArticleId><ArticleId IdType="pubmed">32947927</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattler K., Levkau B. Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection. Cardiovasc Res. 2009;82(2):201&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">19233866</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kessel S.A.M., Olde Hartman T.C., Lucassen P.L.B.J., van Jaarsveld C.H.M. Post-acute and long-COVID-19 symptoms in patients with mild diseases: a systematic review. Fam Pract. 2022;39(1):159&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8414057</ArticleId><ArticleId IdType="pubmed">34268556</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu E., Xie Y., Al-Aly Z. Risks and burdens of incident dyslipidaemia in long-COVID-19: a cohort study. lancet Diabetes Endocrinol. 2023;11(2):120&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9873268</ArticleId><ArticleId IdType="pubmed">36623520</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Geng X., Tan Y., Li Q., Xu C., Xu J., et al. New understanding of the damage of SARS-CoV-2 infection outside the respiratory system. Biomed Pharmacother. 2020;127</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7186209</ArticleId><ArticleId IdType="pubmed">32361161</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao T., Wang C., Duan B., Yang P., Wu J., Zhang Q. Altered lipid profile in COVID-19 patients and metabolic reprogramming. Front Microbiol. 2022;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9133671</ArticleId><ArticleId IdType="pubmed">35633693</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>